phosphate Inhibitors
1 drugsAbout phosphate
Phosphate is an inorganic chemical vital for numerous biological processes. While its precise mechanisms in disease are still being researched, it has emerged as a target of interest in drug development.
Currently, there is no genetic evidence directly linking phosphate to specific diseases, highlighting an area for future research. Modulating phosphate levels could unlock new treatment strategies for a range of conditions.
AURYXIA is the only FDA-approved drug targeting phosphate, indicated for three conditions and developed by KERYX BIOPHARMS. It is a small molecule, representing the sole modality in this therapeutic area.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Endometrial Cancer with only 1 trials.
Top Drugs
KERYX BIOPHARMS is the only company with an approved drug targeting phosphate.
Low competition suggests an opportunity for new entrants, but also indicates potential challenges in the therapeutic area.
Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets phosphate, using small molecule modality.
Exploring alternative modalities like antibodies or biologics could provide a competitive advantage.
Clinical Trials 44 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 12 | 9 | 0 | 3 | 100% |
| Phase 2 | 7 | 5 | 0 | 2 | 100% |
| Phase 3 | 16 | 12 | 1 | 2 | 92% |
| Phase 4 | 9 | 5 | 2 | 2 | 71% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Drug Approval Timeline (2014 - 2014)
The first and most recent drug approval for a phosphate target was AURYXIA in 2014.
The lack of recent approvals suggests a potentially saturated market or challenges in developing new phosphate-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 28 clinical trials targeting phosphate.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities